Greenwich LifeSciences, Inc. financial data

Symbol
GLSI on Nasdaq
Location
3992 Bluebonnet Dr, Building 14, Stafford, TX
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 84.4 % +565%
Return On Equity -1.04K % -463%
Return On Assets -565 % -244%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13.9M shares +5.4%
Common Stock, Shares, Outstanding 13.8M shares +4.94%
Entity Public Float 101M USD +78.5%
Common Stock, Value, Issued 13.8K USD +4.95%
Weighted Average Number of Shares Outstanding, Basic 13.6M shares +3.8%
Weighted Average Number of Shares Outstanding, Diluted 13.6M shares +3.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 15.8M USD +73%
General and Administrative Expense 3.8M USD +132%
Operating Income (Loss) -19.6M USD -82%
Net Income (Loss) Attributable to Parent -19.5M USD -85.6%
Earnings Per Share, Basic -1 USD/shares -86.1%
Earnings Per Share, Diluted -1 USD/shares -86.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.81M USD -34.6%
Assets 3.81M USD -34.6%
Accounts Payable, Current 1.05M USD
Employee-related Liabilities, Current 207K USD +206%
Liabilities, Current 1.62M USD +92.5%
Liabilities 1.62M USD +92.5%
Retained Earnings (Accumulated Deficit) -77.6M USD -33.5%
Stockholders' Equity Attributable to Parent 2.18M USD -56.1%
Liabilities and Equity 3.81M USD -34.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.83M USD -2.91%
Net Cash Provided by (Used in) Financing Activities 492K USD +64.6%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 13.8M shares +4.94%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.34M USD +9.53%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.81M USD -34.6%
Deferred Tax Assets, Valuation Allowance 6.3M USD +39.8%
Deferred Tax Assets, Operating Loss Carryforwards 6.3M USD +39.8%
Share-based Payment Arrangement, Expense 4.22M USD +129%